New Risk • 11h
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Revenue is less than US$1m (AU$406k revenue, or US$289k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$948k net loss in 2 years). Market cap is less than US$100m (AU$50.5m market cap, or US$36.0m). Price Target Changed • May 04
Price target decreased by 10.0% to AU$0.099 Down from AU$0.11, the current price target is provided by 1 analyst. New target price is 725% above last closing price of AU$0.012. Stock is up 50% over the past year. The company is forecast to post a net loss per share of AU$0.10 next year compared to a net loss per share of AU$0.0026 last year. Reported Earnings • Mar 02
First half 2026 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2025) First half 2026 results: EPS: AU$0 (improved from AU$0.001 loss in 1H 2025). Revenue: AU$96.8k (down 85% from 1H 2025). Net loss: AU$1.40m (loss narrowed 36% from 1H 2025). Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Annuncio • Feb 18
AnteoTech Limited to Report First Half, 2026 Results on Feb 25, 2026 AnteoTech Limited announced that they will report first half, 2026 results on Feb 25, 2026 New Risk • Jan 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$969k revenue, or US$683k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$500k net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$46.4m market cap, or US$32.7m). Annuncio • Jan 27
AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 3.80835 million. AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 3.80835 million.
Security Name: Ordinary Share
Security Type: Common Stock
Securities Offered: 245,699,993
Price\Range: AUD 0.0155
Discount Per Security: AUD 0.00093
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Annuncio • Oct 03
AnteoTech Limited, Annual General Meeting, Nov 26, 2025 AnteoTech Limited, Annual General Meeting, Nov 26, 2025. Reported Earnings • Aug 28
Full year 2025 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in FY 2024) Full year 2025 results: AU$0.003 loss per share (improved from AU$0.004 loss in FY 2024). Revenue: AU$3.46m (up AU$3.00m from FY 2024). Net loss: AU$6.76m (loss narrowed 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Annuncio • Aug 14
AnteoTech Limited to Report Fiscal Year 2025 Results on Aug 28, 2025 AnteoTech Limited announced that they will report fiscal year 2025 results on Aug 28, 2025 New Risk • Apr 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (AU$24.3m market cap, or US$15.6m). Annuncio • Apr 24
AnteoTech Limited to Report Q3, 2025 Results on Apr 30, 2025 AnteoTech Limited announced that they will report Q3, 2025 results on Apr 30, 2025 New Risk • Feb 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (AU$37.9m market cap, or US$23.9m). Annuncio • Feb 12
AnteoTech Limited to Report First Half, 2025 Results on Feb 26, 2025 AnteoTech Limited announced that they will report first half, 2025 results on Feb 26, 2025 Annuncio • Nov 20
AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 3.5 million. AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 3.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 175,000,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Transaction Features: Subsequent Direct Listing Annuncio • Oct 02
AnteoTech Limited, Annual General Meeting, Nov 26, 2024 AnteoTech Limited, Annual General Meeting, Nov 26, 2024. New Risk • Aug 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.6m free cash flow). Earnings have declined by 28% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (AU$4.3m revenue, or US$2.9m). Market cap is less than US$100m (AU$51.8m market cap, or US$35.2m). Reported Earnings • Aug 28
Full year 2024 earnings released: AU$0.004 loss per share (vs AU$0.006 loss in FY 2023) Full year 2024 results: AU$0.004 loss per share (improved from AU$0.006 loss in FY 2023). Net loss: AU$8.88m (loss narrowed 30% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings. Annuncio • Aug 22
AnteoTech Limited to Report Fiscal Year 2024 Results on Aug 28, 2024 AnteoTech Limited announced that they will report fiscal year 2024 results on Aug 28, 2024 New Risk • May 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m (AU$1.0m revenue, or US$671k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$55.4m market cap, or US$36.4m). Annuncio • Apr 28
AnteoTech Limited, Annual General Meeting, May 28, 2024 AnteoTech Limited, Annual General Meeting, May 28, 2024, at 11:30 E. Australia Standard Time. Location: the offices of Sparke Helmore Lawyers, Level 23, 240 Queen Street Brisbane Queensland Australia Agenda: To consider ratification of prior issue of placement shares; to consider ratification of prior issue of SPP shares; to consider approval of issue of new options; to consider approval of issue of placement shares and new options to directors; and to consider other matters. Annuncio • Apr 10
AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 5.4 million. AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 5.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 216,000,000
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Annuncio • Apr 09
AnteoTech Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. AnteoTech Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 100,000,000
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Security Features: Attached Options Annuncio • Feb 23
AnteoTech Limited to Report First Half, 2024 Results on Feb 28, 2024 AnteoTech Limited announced that they will report first half, 2024 results on Feb 28, 2024 Annuncio • Sep 27
AnteoTech Limited, Annual General Meeting, Nov 14, 2023 AnteoTech Limited, Annual General Meeting, Nov 14, 2023. Reported Earnings • Aug 30
Full year 2023 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2022) Full year 2023 results: AU$0.006 loss per share (further deteriorated from AU$0.005 loss in FY 2022). Net loss: AU$12.7m (loss widened 18% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. New Risk • Aug 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$10m free cash flow). Earnings have declined by 32% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (9.4% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.3m). Market cap is less than US$100m (AU$60.9m market cap, or US$39.4m). Annuncio • Aug 21
AnteoTech Limited to Report Fiscal Year 2023 Results on Aug 30, 2023 AnteoTech Limited announced that they will report fiscal year 2023 results on Aug 30, 2023 New Risk • Jul 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$10m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 32% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.3m). Market cap is less than US$100m (AU$67.6m market cap, or US$45.8m). Annuncio • Jun 27
AnteoTech Limited Announces Retirement of Christopher Parker from the Board of Directors AnteoTech Ltd. announced the retirement of Christopher Parker from the board of directors on 27 June 2023. Mr. Parker was appointed to the company board on 23 April 2019 having previously served as Chief Executive Officer since first joining the company in April 2018. In particular, he held the position of Executive Director from March 2022 to September 2022 during a period of substantial change for the company. Recent Insider Transactions Derivative • Apr 06
Board Member exercised options to buy AU$70k worth of stock. On the 5th of April, Geoffrey Cumming exercised options to buy 2m shares at a strike price of around AU$0.03, costing a total of AU$55k. This transaction amounted to 8.3% of their direct individual holding at the time of the trade. Since June 2022, Geoffrey's direct individual holding has decreased from 25.13m shares to 24.13m. Company insiders have collectively sold AU$289k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 22
First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2022) First half 2023 results: AU$0.002 loss per share (in line with 1H 2022). Net loss: AU$3.55m (loss narrowed 7.2% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Annuncio • Feb 15
AnteoTech Limited Appoints Tsui Min Lian as Chief Marketing Officer, Effective 15 March 2023 AnteoTech Limited announced the appointment of Ms. Tsui Min Lian to the newly created position of Chief Marketing Officer effective 15 March 2023. The appointment of Ms. Lian, initially on a contract basis, is part of the Company's increasing focus on becoming a marketing lead sales-driven business. Ms. Lian is an experienced sales and marketing leader with extensive local and international experience, having worked for Blue Chip companies, including General Electric, ResMed and Toll Group, where she has been responsible for driving growth and profitability within the business units. As a qualified pharmacist, Ms Lian has a proven track record in commercialisation, translating technology and ideas into new products and services, building strategic partnerships and commercial models within multiple industry sectors with a focus upon the delivery of profitable revenue growth. This experience will bring a new focus upon the Life Sciences and Clean Energy Technology businesses as the Company moves to accelerate the commercialisation of its products and services. Ms. Lian holds an MBA from the University of Adelaide, a Graduate Diploma in Marketing, and a BSc (Hons) Pharmacy from the UK. Recent Insider Transactions • Dec 18
Non-Executive Director recently sold AU$61k worth of stock On the 16th of December, Geoffrey Cumming sold around 1m shares on-market at roughly AU$0.061 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$443k more than they bought in the last 12 months. Board Change • Nov 16
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. 1 highly experienced director. Non-Executive Director Geoff Cumming is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Nov 03
AnteoTech Ltd Announces Halt of European Rat Clinical Trial to Refocus Initiatives AnteoTech Ltd. announced that following the first stage of an operational review, a decision has been made to halt the EuGeni SARS-CoV-2 Ag RDT1 European clinical trial and divert resources and funding from the trial to enable the acceleration of the COVID- 19 Flu A /Flu B Multiplex and/or other Point of Care (POC) tests currently being considered by AnteoTech's New Product Council. The background to the decision includes: - A small number of outliers which have adversely affected the performance of the EuGeni SARS-CoV-2 Ag RDT have been identified. These results are inconsistent with its previously reported performance and these outliers are concentrated in one geographic region. - The test's performance, when excluding the outliers, remains consistent with results reported from the Australian Clinical trial (87.76% sensitivity and 100% specificity2). - Further root cause analysis will be conducted to identify the cause of the outliers prior to continuing the pursuit of sales opportunities in Europe. - Decreasing significance is being placed on Common List requirements for sales into European countries, with the EU Digital COVID Certificate regulation that supports the Common List expected to expire on 30 June 2023. - There is increasing support and focus from health authorities, including the World Health Organisation, on Combo COVID-19 Flu A /Flu B testing. - Discontinuation of the trial enables a reallocation of staff resources and cash in the order of $700,000 to be allocated to the acceleration of future POC diagnostic tests under consideration by AnteoTech's New Product Council. - For the time being the Company has made the decision not to pursue additional regulatory approvals for the single COVID-19 test. Annuncio • Oct 31
AnteoTech Limited Appoint Executives AnteoTech Ltd. announced the appointment of Ms Katrina Byrne as Chief Operating Officer and the transition of Dr. Charlie Huang into the position of Chief Innovation Officer. In parallel, the Company will commence a recruitment process for a Chief Marketing Officer to further develop the marketing initiatives underway within the Company These changes reflect the Company's internal repositioning and align strategically with its transition from a pure research and development (R&D) company to a market-led sales driven business servicing customers across multiple sectors. As Chief Operating Officer, Ms Byrne will take a leadership role in building an organisational structure that facilitates the acceleration of project developments in AnteoTech's two core operating divisions - Life Sciences and Energy. With advanced research operations across its project suite, AnteoTech has a unique opportunity to find commercial solutions through shared information and the broader knowledge base of its staff and leadership team. Ms Byrne's career experience in project management makes her the ideal candidate to help establish a nimble structure that will allow AnteoTech to move quickly with respect to the commercialisation of R&D breakthroughs. The transition of Dr. Huang to Chief Innovation Officer (CIO) is also targeted at the achievement of those same commercialisation objectives. As Head of the Diagnostics and Life Science division since 2019, Huang has presided over the intellectual property portfolio and a multi-year clinical research operation for the group's EuGeni platform, which includes a novel detection technology for the COVID-19 virus and disease biomarkers. In his role as CIO, Huang will be responsible for the development of advanced technologies and innovative approaches to address market opportunities identified by the newly formed New Product Council primarily in the Life Sciences segment while also providing technical support to the Energy group to help accelerate commercialisation of the AnteoX and lithium-ion battery technology. Katrina Byrne joined AnteoTech as Head of Programs in July 2022 and will commence as Chief Operating Officer effective 31st October 2022. Katrina has extensive domestic and international experience in operations, projects, and supply chain management across multiple industries including aerospace, defence, electronics manufacturing and resources, with a proven track record of growing and developing teams to facilitate the development and introduction of new products and capabilities. Her experience includes five years at Boeing introducing new products and capabilities in roles such as Operations Manager of the global Phantom Works division responsible for the rapid prototyping and development of advanced technologies. More recently Katrina worked with Airbus Australia Pacific (AAP) as Program Manager, Commercial Operations & Offers. Katrina was a past Board Member of Women in Aviation International, Australian Chapter. She holds an MBA from the Australian Graduate School of Management and a Bachelor of Engineering - Manufacturing & Materials (Hons) from the University of Queensland. Dr. Charlie Huang joined AnteoTech in 2013 as Head of R&D and was appointed Head of Diagnostics and Life Science in 2019. Charlie will commence as Chief Innovation Officer effective 31st October 2022. Prior to joining AnteoTech, he has held senior multi-discipline management roles in several listed healthcare and in vitro diagnostics companies including Panbio Ltd, Alere, Cellestis Ltd. and QIAGEN. He is working with the AnteoTech team to develop strategies, patents, products and services for industrial and life science applications and commercialisation. He holds a BSc in Life Science and an MSc in Molecular Engineering from National Chung Hsing University, Taiwan. He obtained his PhD in Biochemistry and Molecular Biology from the University of Queensland. Reported Earnings • Aug 24
Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.003 loss in FY 2021) Full year 2022 results: AU$0.005 loss per share (down from AU$0.003 loss in FY 2021). Net loss: AU$10.7m (loss widened 72% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 70% per year, which means it is well ahead of earnings. Annuncio • Aug 24
AnteoTech Limited, Annual General Meeting, Nov 17, 2022 AnteoTech Limited, Annual General Meeting, Nov 17, 2022. Annuncio • Jun 24
AnteoTech Limited SHS to Be Deleted from OTC Equity AnteoTech Limited SHS (Australia) will be deleted from OTC Equity effective from June 24, 2022, due to Inactive Security. Recent Insider Transactions • Jun 18
Non-Executive Director recently sold AU$106k worth of stock On the 14th of June, Geoffrey Cumming sold around 2m shares on-market at roughly AU$0.071 per share. In the last 3 months, they made an even bigger sale worth AU$220k. Insiders have been net sellers, collectively disposing of AU$461k more than they bought in the last 12 months. Annuncio • May 18
AnteoTech Ltd Announces Updated COVID-19 RAT Receives Regulatory Approval in Europe AnteoTech Ltd. announced that it has successfully registered an updated EuGeni COVID-19 Rapid Antigen Test (RAT)1 in Europe under the In Vitro Diagnostic Directive (IVDD) 98/79/EC Regulations. The new registration strengthens the EuGeni COVID -19 RAT's competitive position as it broadens and aligns sampling methods to current trends in standard of care for the European market. The updated test will provide additional leverage as AnteoTech expands the EuGeni COVID-19 RAT footprint in Europe. The new registration is for the same core SARS-CoV-2 Ag Rapid Diagnostic Test registered in April 2021 but now covers multiple use claims (sampling methods) to include combined nose and throat sampling and nasal mid-turbinate sampling on top of the original nasopharyngeal sampling method. To establish the new use claims, AnteoTech completed analytical and clinical performance evaluations in the US and the UK respectively, that focussed on validating the test's effectiveness in detecting the Omicron variant of SARS-CoV-2, the dominant variant currently circulating globally. This work will be used in future regulatory submissions. The European Clinical Trial currently underway is also evaluating the updated multiple-use claim, to enable this to be included in the EU Common List registration application. As AnteoTech receives orders for the updated multiple-use claim test kits, the original nasopharyngeal test will be phased out. Recent Insider Transactions • May 06
Non-Executive Director recently sold AU$220k worth of stock On the 3rd of May, Geoffrey Cumming sold around 2m shares on-market at roughly AU$0.11 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$382k more than they bought in the last 12 months. Board Change • Apr 27
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. Non-Executive Director Geoff Cumming is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Apr 21
AnteoTech Limited Announces Executive Changes The Board of AnteoTech Limited announced the appointment of Mr. Ewen Crouch AM as Non-Executive Director and Chairman-Elect succeeding Dr. Jack Hamilton on 30 April 2022. Dr. Hamilton's retirement from the board will be effective on 30 April 2022. Mr. Crouch is currently Chairman of Corporate Travel Management Limited and serves on the Boards of Bluescope Steel Limited and respected Australian non-profit organisation Jawun. From 1988-2103 Mr. Crouch was a partner at Allens. Reported Earnings • Mar 02
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat First half 2022 results: AU$0.002 loss per share (down from AU$0.001 loss in 1H 2021). Net loss: AU$3.82m (loss widened 161% from 1H 2021). Revenue exceeded analyst estimates by 73%. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 117% per year, which means it is well ahead of earnings. Annuncio • Feb 11
AnteoTech Limited Provides Update on Its Therapeutic Goods Administration Submission AnteoTech Ltd. provided an update on its Therapeutic Goods Administration (TGA) submission for the registration of its EuGeni Reader and SARS CoV-2 Ag Rapid Diagnostic Test (RDT). In response to TGA's review of the submission, AnteoTech intends to collect further clinical data based on samples collected directly from patients and immediately analysed on the EuGeni Reader (prospective samples). Australian and European clinical research organizations are coordinating these clinical trials. AnteoTech has had ongoing and constructive discussions with the TGA over the past week. These discussions focused on the reconciliation of AnteoTech's clinical data set, which includes stored and direct patient samples, and the TGA's requirements for additional clinical evidence. Following these discussions, it has been concluded that AnteoTech's proposed approach of conducting new clinical trials represents the most expeditious pathway to meeting these data requirements. The data generated from these trials will ensure that a new submission by AnteoTech will meet the TGA's regulatory requirements, as well as providing the Company with data for additional regulatory approval processes, including registration for the EU Common List. The trials will also provide further evidence of performance relating to new variants of concern listed by the World Health Organisation ("WHO"), lower limit of detection and other performance measures from a vaccinated population. By undertaking a new submission, AnteoTech has the flexibility and opportunity to compile the new clinical data from studies in Australia and Europe and present this as a fresh and unencumbered submission to the TGA. AnteoTech will provide updates as key milestones are achieved. Recent Insider Transactions • Dec 27
Non-Executive Director recently sold AU$108k worth of stock On the 23rd of December, Geoffrey Cumming sold around 500k shares on-market at roughly AU$0.22 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$162k more than they bought in the last 12 months. Executive Departure • Dec 01
Company Secretary Duncan Cornish has left the company On the 30th of November, Duncan Cornish's tenure as Company Secretary ended after 2.8 years in the role. As of September 2021, Duncan still personally held 962.15k shares (AU$255k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.79 years. Board Change • Nov 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. 1 highly experienced director. Non-Executive Director Geoff Cumming is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Oct 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. 1 highly experienced director. Non-Executive Director Geoff Cumming is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Sep 22
Independent Non-Executive Director recently bought AU$59k worth of stock On the 17th of September, Glenda McLoughlin bought around 250k shares on-market at roughly AU$0.23 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold AU$183k more in shares than they bought in the last 12 months. Board Change • Sep 11
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Jack Hamilton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 09
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Jack Hamilton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 08
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Jack Hamilton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 06
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Jack Hamilton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 05
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Jack Hamilton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 01
Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.002 loss in FY 2020) Full year 2021 results: Net loss: AU$6.22m (loss widened 99% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 133% per year, which means it is well ahead of earnings. Executive Departure • Sep 01
Chief Financial Officer Gail Jukes has left the company On the 31st of August, Gail Jukes' tenure as Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Gail's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.50 years. Recent Insider Transactions • Aug 03
Non-Executive Director recently sold AU$112k worth of stock On the 2nd of August, Geoffrey Cumming sold around 500k shares on-market at roughly AU$0.22 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$241k more than they bought in the last 12 months. Annuncio • May 05
AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 12.000001 million. AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 12.000001 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 46,153,851
Price\Range: AUD 0.26
Discount Per Security: AUD 0.0156
Transaction Features: Subsequent Direct Listing Annuncio • Apr 28
AnteoTech Limited announced that it expects to receive AUD 12.000001 million in funding AnteoTech Limited (ASX:ADO) announced it has secured firm commitments for private placement of 46,153,851 shares at a price of AUD 0.26 per share for gross proceeds of AUD 12,000,001.26 on April 28, 2021. The transaction will include participation from range of new institutional and sophisticated investors. Shares from the placement will be issued under the company’s existing capacity under ASX Listing Rule 7.1 and will be issued on or around May 5, 2021. Executive Departure • Apr 24
Independent Non-Executive Director has left the company On the 22nd of April, Matthew Sanderson's tenure as Independent Non-Executive Director ended after 3.5 years in the role. As of December 2020, Matthew personally held 10.28m shares (AU$1.1m worth at the time). Matthew is the only executive to leave the company over the last 12 months. Reported Earnings • Mar 04
First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2020) The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: AU$1.75m (up 65% from 1H 2020). Net loss: AU$1.47m (loss widened 33% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 134% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 10
New 90-day high: AU$0.21 The company is up 153% from its price of AU$0.085 on 12 November 2020. The Australian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 14% over the same period. Annuncio • Feb 03
AnteoTech Customer Ellume Secures Us Contract AnteoTech Ltd. announced an agreement with the U.S. Department of Defense (DOD) for its Emergency Use Authorization (EUA) COVID 19 at home test. As announced on 28 October 2016, Ellume integrates AnteoBind technology in their proprietary quantum dot diagnostics platform. The Ellume COVID-19 home test, incorporating AnteoBind, is the first non-prescription over-the-counter self-test authorized by the U.S. Food and Drug Administration for emergency use. Ellume and AnteoTech have a supply contract which has been in place since 2016 and is due for renewal in late 2021. Ellume's announcement in regard to its new US contract does not trigger the need for any immediate
alteration to AnteoTech's supply contract conditions with Ellume. AnteoTech's supply strategy is to support assay development of key customers via use of surface coating technology - AnteoBind. AnteoBind is a key element of AnteoTech's own COVID-19 Antigen Rapid Test currently in development and several other assays marketed globally. Ellume's announcement is a welcome event that is a demonstration of AnteoTech's importance in helping deliver key diagnostic products to global markets. Annuncio • Dec 24
AnteoTech Progresses COVID-19 Test Toward Market Launch AnteoTech Ltd. provided a brief update on the COVID-19 Antigen Rapid Test (ART) development program. Since signing a Memorandum of Understanding with Operon in Spain, announced to the market on 26 November 2020, AnteoTech has been working with the Operon team to facilitate the technology transfer that will enable scaled manufacturing of the COVID-19 test. This transfer process is on track and once finalised, will facilitate the implementation of a manufacturing agreement with Operon. AnteoTech has also signed an agreement with a Spanish company to commence manufacturing of the plastic cassettes that hold the test strips that are inserted into the reader. This company is conveniently located close to Operon's manufacturing plant, reducing supply chain processes for this high volume element of the product. Annuncio • Nov 28
AnteoTech Ltd Freeze Design of COVID-19 Antigen Rapid Test After Showing Saliva Proxy Sample Use Case Effectiveness AnteoTech Ltd. announced that all development processes and internal testing procedures for the high sensitivity COVID-19 Antigen Rapid Test (ART) are complete and the Company has declared a "design freeze" for the product. Attributes of COVID-19 Antigen Rapid Test final design include: Test completion in cassette in under 15 minutes which includes less than 1-minute analysis time in reader. High Sensitivity - 0.02 ng/ml antigen concentration and positive sample detection in low viral load samples (Ct value of 30 and above). Inhouse experiments have detected antigen in artificial mucus mimicking saliva samples. To date the development of AnteoTech's ART has focussed on the use of nasopharyngeal swab samples, however recent lab testing conducted by AnteoTech using artificial mucus indicates that good detection of SARS-CoV-2 antigen at low viral loads can also be obtained in human saliva, opening the opportunity for integration of a saliva test, once validated independently, into the existing nasopharyngeal test protocol. The test used an artificial mucus developed from natural mucin and electrolyte to produce a liquid which replicates the viscosity and elements of saliva to mimic saliva and mucus produced by the salivary glands in the mouth. The artificial mucus was spiked with inactivated SARS-CoV-2 virus simulating varying viral loads from real world examples. Saliva and mucus from the mouth is naturally expected to carry lower amounts of antigen when compared with nasopharyngeal swab samples obtained from the same patient. Seven different viral load levels were produced, the lowest level simulating a viral load typically seen in patients' early stage of infection (pre symptom onset) or late stage of infection. Each viral load level was tested 6 times result being recorded for each iteration of the test. This was repeated for all seven viral levels. The ability to detect signals from artificial mucus samples spiked with low antigen load again confirms the sensitivity of AnteoTech's ART test. These internal results are subject to external validation and clinical trial. All development work required to declare a `design freeze', the point at which the technical work and inputs are locked in, has now occurred in line with its development schedule and budget. This includes finalisation of key contracts for the procurement of antibodies and Europium particles. The design freeze incorporates both artificial mucus and nasopharyngeal swab sample protocols. Recent Insider Transactions Derivative • Nov 25
Independent Non-Executive Director exercised options to buy AU$208k worth of stock. On the 23rd of November, Matthew Sanderson exercised options to buy 2.63m shares at a strike price of around AU$0.02, costing a total of AU$53k. This transaction amounted to 34% of their direct individual holding at the time of the trade. Since March 2020, Matthew has owned 7.66m shares directly. This was the only transaction from an insider over the last 12 months. 
